Congress Materials
Encore posters are re-presentations of previously published data.
Filter by:
Year
Year
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Filter by:
Year
Year
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Results124
Sort by
Patients With Focal Segmental Glomerulosclerosis (FSGS) Reach Proteinuria <0.7 g/g More Often With Sparsentan vs Irbesartan in DUPLEX: Implications for Kidney Failure Risk
American Society of Nephrology (ASN) Kidney Week – 2025
Patients With Focal Segmental Glomerulosclerosis (FSGS) Reach Proteinuria <0.7 g/g More Often With Sparsentan vs Irbesartan in DUPLEX: Implications for Kidney Failure Risk
American Society of Nephrology (ASN) Kidney Week – 2025
Sparsentan vs. Irbesartan in Pediatric Patients with Focal Segmental Glomerulosclerosis (FSGS) in the Phase 3 DUPLEX Trial
American Society of Nephrology (ASN) Kidney Week – 2025
Sparsentan vs. Irbesartan in Pediatric Patients with Focal Segmental Glomerulosclerosis (FSGS) in the Phase 3 DUPLEX Trial
American Society of Nephrology (ASN) Kidney Week – 2025
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy
American Society of Nephrology (ASN) Kidney Week – 2025
Impact of Histology on Efficacy of Sparsentan Therapy in IgA Nephropathy: Central Biopsy Review of Patients in the PROTECT Trial
American Society of Nephrology (ASN) Kidney Week – 2025
Join the
Conversation
Sign up to receive updates on the latest news, resources, and data on rare disease research.
Connect with our MSL team today
Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.
Find your MSL